Compare BioNTech SE - ADR (BNTX) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs The Coca-Cola Co K — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while The Coca-Cola Co K trades at $86.49 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 16× BioNTech SE - ADR's market cap, and The Coca-Cola Co K pays a 2.44% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | KO | |
|---|---|---|
Market Cap | $23.31B | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $89.08 |
52-Week Low | $83.89 | $65.67 |
Enterprise Value | $6.60B | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.
The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
